SILO

Silo Pharma, Inc. (SILO) Risks & Opportunities Analysis (2026)

Invetso Score: 6.1/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 5.8 (Moderate)

Negative interest coverage and modest net debt versus EBITDA increase refinancing sensitivity if earnings weaken, though low leverage is less stretched than many small-cap peers.

An extremely long cash conversion cycle driven by supplier financing can support liquidity, but it also leaves SILO more exposed than peers to payables normalization and working-capital shocks.

High current and quick ratios indicate near-term liquidity strength, yet that cushion may not fully offset volatility in a small-cap model versus larger, better-diversified peers.

Limited profitability visibility, reflected in missing FCF margin data, makes peer-relative valuation and capital allocation outcomes harder to underwrite than for consistently cash-generative competitors.

Opportunities

Score:

Strong liquidity and low net debt provide balance-sheet flexibility to absorb demand swings and fund growth initiatives more easily than more leveraged peers.

The negative cash conversion cycle creates a working-capital funding source that can support operations and near-term expansion if supplier terms remain favorable versus peers.

If operating performance stabilizes, the current liquidity profile could translate into faster deleveraging and improved financing terms relative to weaker small-cap competitors.

Compared with peers facing tighter liquidity, SILO has more room to navigate cyclical or customer-specific volatility without immediate capital pressure.

Overall Score

Score:

SILO’s strong liquidity and low leverage support resilience versus peers, but weak interest coverage and working-capital dependence keep forward positioning only moderately attractive.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Silo Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →